(Q43037279)

12 November 2017

0 references

Meta-analysis: insulin resistance and sustained virological response in hepatitis C. (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

1 reference

M Eslam

1

1 reference

12 November 2017

R Aparcero

2

1 reference

12 November 2017

T Kawaguchi

3

1 reference

12 November 2017

J A Del Campo

4

1 reference

12 November 2017

M Sata

5

1 reference

12 November 2017

M A Khattab

6

1 reference

12 November 2017

M Romero-Gomez

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

29 May 2011

1 reference

Alimentary Pharmacology & Therapeutics

12 November 2017

1 reference

12 November 2017

34

1 reference

12 November 2017

3

1 reference

12 November 2017

297-305

1 reference

The epidemiology of acute and chronic hepatitis C.

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

The history of the "natural history" of hepatitis C (1968-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Targeting host factors: A novel rationale for the management of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Toward standardization of insulin immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04716.X

10.1111/J.1365-2036.2011.04716.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference